AlpE offers first human proof that VirS/MymA potentiation can restore ethionamide activity, with 45mg AlpE and 250mg RZE showing numerically similar 14-day early bactericidal activity to HRZE in newly diagnosed drug-sensitive pulmonary tuberculosis in the ENABLE trial (NCT06748937). [1] The signal is dose-dependent and supported by preclinical activity on isoniazid- and ethionamide-resistant strains including inhA promoter mutants with lowered spontaneous resistance frequency, directly addressing isoniazid resistance occurring in 7.5% of UK cases where treatment is not always successful. [2] Yet no closely comparable precedent exists because no prior VirS-targeted booster shares both mechanism and clinical context, so translation cannot borrow weight from bedaquiline modified shorter regimens reporting 78.5% pooled success in 8166 patients and 82.7% success in 2636 participants, or from the APT randomized Phase 2 reporting median liquid culture negativity of 42, 28 and 56 days. [3][4] Those programs rest on randomized Phase 2 and cohort evidence tiers above 14-day EBA, with durable endpoints of mortality, treatment success or failure, relapse and resistance emergence required for isoniazid-resistant regimens under Tuberculosis NG33. [5][1] Regulatory advancement will require full combination development with prolonged safety for myelosuppression, neuropathy, QTcF and hepatotoxicity and relapse follow-up to 22 months, leaving AlpE early-stage against bedaquiline-linezolid and pretomanid-based short regimens. [1]
ENABLE Phase IIa 14-day EBA with numerically similar activity to HRZE and acceptable safety, without mortality, treatment success, relapse or resistance data. [5]
| Indication | Pulmonary Tuberculosis (TB) |
| Drug | AlpE (ethionamide and alpibectir) |
| Company | BioVersys |
| Trial Phase | Phase IIa |
| Trial Acronym | ENABLE |
| NCT ID | NCT06748937 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Infectious Diseases & Vaccines |
| Patient Population | Newly diagnosed, drug-sensitive pulmonary TB patients |
| Trial Duration | 14 days |
| Comparator Regimen | HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol) |
| Dosage (AlpE) | 45mg |
| Combination Partner (RZE) | rifampicin, pyrazinamide, ethambutol |
| Presentation Venue | Union World Conference on Lung Health, Brazil |
| Collaborating Organizations | GSK, UNITE4TB |
| AMR Funding Agency | US’s Biomedical Advanced Research and Development Authority (BARDA) |
| AMR Funding Amount | $482m |
| WHO Priority Pathogens Guidance | Antibiotic development directed to priority pathogens |
BioVersys' AlpE Shows Promise in Phase IIa TB Trial
Swiss biopharmaceutical company BioVersys announced positive results from its 14-day Phase IIa ENABLE trial (NCT06748937) evaluating the antibiotic combination AlpE in patients with newly diagnosed, drug-sensitive pulmonary tuberculosis (TB). AlpE, comprising ethionamide and novel small molecule alpibectir, was tested as a standalone treatment and in combination with rifampicin, pyrazinamide, and ethambutol (RZE) to replace isoniazid in the standard-of-care HRZE regimen. All tested regimens demonstrated bacteria-killing activity, with the effect dependent on the ethionamide dose. A regimen of 45mg AlpE and 250mg RZE showed numerically similar early bacteria-killing activity to HRZE, suggesting AlpE's potential to replace isoniazid for drug-resistant patients. The drug also exhibited an acceptable safety profile.
- The Phase IIa ENABLE trial demonstrated that BioVersys' AlpE combination, particularly when administered as 45mg AlpE alongside 250mg RZE, achieved early bacteria-killing activity numerically similar to the standard-of-care HRZE regimen. This finding is significant as it suggests AlpE's potential to serve as a viable replacement for isoniazid, especially for patients who exhibit resistance to the current first-line anti-TB drug.
- Beyond its promising efficacy, AlpE was generally well-tolerated by patients over the 14-day study period, with BioVersys reporting an "acceptable" safety profile. This favorable tolerability is crucial for a new antibiotic, particularly given the long treatment durations often required for tuberculosis, and supports its continued evaluation as a potential component of simpler and more effective future TB regimens.
- These positive results for AlpE are particularly timely given the escalating global threat of antimicrobial resistance (AMR), which the World Health Organization classifies as a major health concern. The development of AlpE, supported by a collaboration with GSK and the European public-private partnership UNITE4TB, aligns with broader efforts to accelerate clinical trials for novel TB treatments and build a new arsenal against drug-resistant pathogens.
Addressing the Urgent Challenges in Pulmonary TB Treatment
Current treatment for drug-susceptible tuberculosis is effective in ≥95% of disease cases, yet supervised therapy for ≥6 months is challenging and real-world success remains below targets. Effective treatment of MDR-TB involves therapy with 5-7 less effective, expensive, and toxic second-line and third-line drugs for ≥24 months and is difficult in most developing countries, while XDR-TB is generally an untreatable disease in developing countries.
Prolonged, complex regimens with poor completion: Duration of TB treatment and follow-up medical visits were not applied as recommended in more than a third of cases, and treatment success 70.1% (95%CI 66.5-73.7) is below the World Health Organization target of 85%. Non-completion of treatment was associated with sputum smear positivity, injection drug use, non-adherence and irregular follow-up in univariate analysis, and with irregular follow-up and non-adherence in multivariate analysis.
Non-adherence driving resistance: Non-adherence to anti-tuberculosis (TB) treatment adversely affects treatment success rate, increases disease morbidity and mortality, and contributes significantly to the development of drug resistance. Out of 156 newly diagnosed pulmonary TB patients, 78 (50%) were non-adherent to anti-tuberculosis treatment (ATT), with independent risk factors identified as male gender (P = 0.035) and lack of knowledge of importance of regular treatment (P = 0.001). Non-adherence to treatment often results in the evolution of drug-resistant strains of M. tuberculosis due to mutations in the genes encoding drug targets, with sequential accumulation of mutations resulting in the evolution of MDR and XDR strains.
Toxicity and tolerability limiting adherence: Isoniazid (INH) has been the mainstay of treatment of latent tuberculosis infection for almost 50 years with efficacy of more than 90% if completed properly, but INH is associated with serious adverse events, including hepatotoxicity, requiring close follow up of patients and increasing cost and complexity. Sputum conversion, adverse effects and adherence to MDR-TB treatment should be monitored closely, and the lengthy duration results in poor acceptance by patients and providers, and poor adherence by patients.
Inadequate retreatment strategies and risk of amplifying resistance: The Category II retreatment regimen is inadequate for Category I failures if multidrug-resistant TB (MDR-TB) is present, and modification of regimens for mono- and polyresistance is prone to error if DST results are not reliable or if there is possible additional drug resistance due to further drug exposure. Fluoroquinolones (FQs) should be used with caution in the treatment of mono- and polyresistant TB, the presence of FQ resistance prior to MDR-TB treatment poses a serious challenge, and strategies to protect the FQs, the most important second-line agents, need to be developed to prevent the development of extensively drug-resistant TB.
Persistently poor outcomes in vulnerable groups despite therapy: Children with human immunodeficiency virus (HIV, CWH) are at high risk of tuberculosis (TB) and face poor outcomes, despite antiretroviral therapy (ART), with CWH more likely to be hospitalized (adjusted odds ratio, 2.4; 1.3-4.6) and to die (adjusted hazard ratio [aHR], 2.6; 95% confidence interval [CI], 1.2 to 5.8). HIV status, age <3 years (aHR, 6.3; 1.5, 27.3), malnutrition (aHR, 6.2; 2.4, 15.9), and hemoglobin <7 g/dL (aHR, 3.8; 1.3,11.5) independently predicted mortality, and improving outcomes in drug-sensitive tuberculosis programmes might require not only better diagnostic tests but also better linkage to care.
Promising Early Efficacy and Safety from AlpE's ENABLE Trial
Rifapentine-based shortening strategies for drug-susceptible pulmonary tuberculosis were evaluated in Study 31/A5349 (NCT02410772), an open-label, phase 3, randomized, controlled trial in persons with newly diagnosed pulmonary tuberculosis from 13 countries. Two 4-month rifapentine-based regimens were compared with a standard 6-month regimen consisting of rifampin, isoniazid, pyrazinamide, and ethambutol (control), using a noninferiority margin of 6.6 percentage points. In one 4-month regimen, rifampin was replaced with rifapentine; in the other, rifampin was replaced with rifapentine and ethambutol with moxifloxacin. The primary efficacy outcome was survival free of tuberculosis at 12 months. Rifapentine with moxifloxacin was noninferior to the control in the microbiologically eligible population (15.5% vs. 14.6% had an unfavorable outcome; difference, 1.0 percentage point; 95% confidence interval [CI], -2.6 to 4.5) and in the assessable population (11.6% vs. 9.6%; difference, 2.0 percentage points; 95% CI, -1.1 to 5.1). Rifapentine without moxifloxacin was not shown to be noninferior to the control in either population (17.7% vs. 14.6% with an unfavorable outcome in the microbiologically eligible population; difference, 3.0 percentage points [95% CI, -0.6 to 6.6]; and 14.2% vs. 9.6% in the assessable population; difference, 4.4 percentage points [95% CI, 1.2 to 7.7]). Adverse events of grade 3 or higher occurred during the on-treatment period in 19.3% of participants in the control group, 18.8% in the rifapentine-moxifloxacin group, and 14.3% in the rifapentine group.
Pretomanid-containing regimens for drug-sensitive pulmonary tuberculosis were evaluated in Assessing Pretomanid for Tuberculosis (APT), a randomized phase 2 trial of pretomanid-containing regimens for drug-sensitive tuberculosis (NCT02256696). The phase 2, 12-week, open-label randomized trial compared isoniazid and pyrazinamide plus 1) pretomanid and rifampicin (arm 1), 2) pretomanid and rifabutin (arm 2), or 3) rifampicin and ethambutol (standard of care; arm 3), with time to culture conversion on liquid medium as the primary outcome. Median time to liquid culture negativity in the modified intention-to-treat population (n = 150) was 42 (arm 1), 28 (arm 2), and 56 (arm 3) days (P = 0.01) (adjusted hazard ratio for arm 1 vs. arm 3, 1.41 [95% confidence interval (CI), 0.93-2.12; P = 0.10]; adjusted hazard ratio for arm 2 vs. arm 3, 1.89 [95% CI, 1.24-2.87; P = 0.003]). Eight-week liquid culture conversion was 79%, 89%, and 69%, respectively. Grade ≥3 adverse events occurred in 3 of 56 (5%), 5 of 53 (9%), and 2 of 56 (4%) participants. Six participants were withdrawn because of elevated transaminase concentrations (five in arm 2, one in arm 1). There were three serious adverse events (arm 2) and no deaths.
All-oral bedaquiline, pretomanid, and linezolid-based regimens for rifampin-resistant and highly drug-resistant pulmonary tuberculosis were evaluated in Treatment of Highly Drug-Resistant Pulmonary Tuberculosis (NCT02333799) and in the open-label, phase 2-3, multicenter, randomized, controlled, noninferiority trial TB-PRACTECAL (NCT02589782). In the single-group study of bedaquiline, pretomanid, and linezolid for 26 weeks in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects, 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome at 6 months after the end of treatment in the intention-to-treat analysis, while 11 patients (10%) had an unfavorable outcome. The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose reductions or interruptions in treatment with linezolid. In TB-PRACTECAL stage 2, a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) was compared with a 9-to-20-month standard-care regimen, with an unfavorable status (a composite of death, treatment failure, treatment discontinuation, loss to follow-up, or recurrence of tuberculosis) at 72 weeks after randomization as the primary outcome. In the modified intention-to-treat analysis, 11% of the patients in the BPaLM group and 48% of those in the standard-care group had a primary-outcome event (risk difference, -37 percentage points; 96.6% confidence interval [CI], -53 to -22). In the as-treated population, the incidence of adverse events of grade 3 or higher or serious adverse events was lower in the BPaLM group than in the standard-care group (19% vs. 59%).
AlpE's Potential to Reshape Standard-of-Care TB Regimens
Four-month fluoroquinolone-containing regimens have been directly compared with the standard six-month regimen comprising isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) for two months followed by HRE or HR. In five randomized trials recruiting 5825 adults with newly diagnosed drug-sensitive pulmonary tuberculosis, moxifloxacin-containing four-month regimens that replaced ethambutol or isoniazid probably increased relapse after successful treatment compared to standard regimens (RR 3.56, 95% CI 2.37 to 5.37; 2265 participants, 3 trials; moderate-certainty evidence). For death from any cause there was probably little or no difference (2760 participants, 3 trials; moderate-certainty evidence), treatment failure was rare with probably little or no difference (2282 participants, 3 trials; moderate-certainty evidence), and severe adverse events were probably little or no different (3548 participants, 4 trials; moderate-certainty evidence). Gatifloxacin-containing four-month regimens that replaced ethambutol probably increased relapse (RR 2.11, 95% CI 1.56 to 2.84; 1633 participants, 2 trials; moderate-certainty evidence), with probably little or no difference in death (1886 participants, 2 trials), treatment failure (1657 participants, 2 trials), and serious adverse events (1993 participants, 2 trials).
In Study 31/A5349 (NCT02410772), an open-label, phase 3 trial in 2516 randomized participants of whom 2343 were microbiologically eligible (768 in the control group, 791 in the rifapentine-moxifloxacin group, and 784 in the rifapentine group), a 4-month rifapentine-based regimen containing moxifloxacin was noninferior to the standard 6-month regimen using a noninferiority margin of 6.6 percentage points. Survival free of tuberculosis at 12 months showed 15.5% vs. 14.6% had an unfavorable outcome in the microbiologically eligible population (difference, 1.0 percentage point; 95% confidence interval [CI], -2.6 to 4.5) and 11.6% vs. 9.6% in the assessable population of 2234 participants (726 in the control group, 756 in the rifapentine-moxifloxacin group, and 752 in the rifapentine group) (difference, 2.0 percentage points; 95% CI, -1.1 to 5.1). Rifapentine without moxifloxacin was not shown to be noninferior (17.7% vs. 14.6% with an unfavorable outcome in the microbiologically eligible population; difference, 3.0 percentage points [95% CI, -0.6 to 6.6]; and 14.2% vs. 9.6% in the assessable population; difference, 4.4 percentage points [95% CI, 1.2 to 7.7]). Adverse events of grade 3 or higher occurred during the on-treatment period in 19.3% of participants in the control group, 18.8% in the rifapentine-moxifloxacin group, and 14.3% in the rifapentine group.
Other shortened and adjunct approaches show mixed signals versus 2HRZE/4HR or 6 months of RHEZ (rifampicin, isoniazid, ethambutol, and pyrazinamide for 8 weeks followed by 18 weeks of rifampin and isoniazid). A proof-of-concept phase 2b/c trial (NCT05221502) in 122 randomized adults found 4 months of delamanid, bedaquiline, and quabodepistat (DBQ) met non-inferiority for sputum culture conversion by end of treatment versus 6 months of RHEZ, with 96.0% (90.1-98.9, 96 of 100 participants) in the pooled DBQ group and 100.0% (83.9-100.0, all 21 participants) in the RHEZ group (difference -4.0% [80% CI -7.4 to 3.4]), and rates of adverse events of grade 3 or higher of 20% in DBQ10, 14% in DBQ30, 11% in DBQ90, and 5% in RHEZ. By contrast, a multicenter trial (NCT04485156) of high-dose rifampicin (30 mg/kg/day) with isoniazid and pyrazinamide until culture conversion followed by high-dose rifampicin and isoniazid for 12 weeks failed to demonstrate non-inferiority at 18 months post-randomization, with unfavorable outcomes in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group (difference 7.2% [95% confidence interval, ∞ to 31.9%]) and no difference in serious adverse events and grade 3 or higher adverse events. In a retrospective analysis of 106 pulmonary tuberculosis patients, thymosin α1 combined with 2HRZE/4HR (control n = 47, observation n = 59) showed higher total effective rate and rates of foci resorption and cavity closure than 2HRZE/4HR alone (p < 0.05), higher FEV1, FVC, FEV1/FVC, and PEF after 6 months (p < 0.05), and no significant difference in incidence of adverse reactions (p > 0.05).
Frequently Asked Questions
References
- [1] Wang X, Zhang H et al.. Rapid and simultaneous determination of ten anti-tuberculosis drugs in human plasma by UPLC-MS/MS with applications in therapeutic drug monitoring. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2020 Sep 1. 32668377
- [2] Nyang'wa BT, Berry C et al.. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. The New England journal of medicine. 2022 Dec 22. 36546625
- [3] Nagar V, Prasad P et al.. Screening for diabetes among tuberculosis patients registered under revised national tuberculosis control program, Bhopal, India. Journal of family medicine and primary care. 2018 Nov-Dec. 30613532
- [4] Chabala C, Wobudeya E et al.. Clinical Outcomes in Children With Human Immunodeficiency Virus Treated for Nonsevere Tuberculosis in the SHINE Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2024 Jul 19. 38592950
- [5] Suh E, Jung S et al.. Prospective Comparative Evaluation of the Xpert MTB/RIF and Xpert MTB/RIF Ultra Assays for Detecting Mycobacterium tuberculosis and Rifampin Resistance in High-resource, Intermediate-burden Settings. Annals of laboratory medicine. 2025 Nov 1. 40947993
- [6] Dorman SE, Nahid P et al.. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. The New England journal of medicine. 2021 May 6. 33951360
- [7] Ndjeka N, Perumal R et al.. Treatment outcomes and drug-related adverse events across four short-course RR-TB regimens in South Africa: A retrospective analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2026 Apr. 41667022
- [8] Menzies D, Long R et al.. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Annals of internal medicine. 2008 Nov 18. 19017587
- [9] Guglielmetti L, Le Dû D et al.. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015 Jan 15. 25320286
- [10] Jain A, Mondal R et al.. Novel mutations in emb B gene of ethambutol resistant isolates of Mycobacterium tuberculosis: a preliminary report. The Indian journal of medical research. 2008 Nov. 19179685
- [11] Mase S, Chorba T et al.. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Aug 14. 31556947
- [12] Li D, Song Y et al.. Screening mutations in drug-resistant Mycobacterium tuberculosis strains in Yunnan, China. Journal of infection and public health. 2017 Sep-Oct. 28623123
- [13] Mahmoud H, Khalifa M et al.. A Two-Front Battle: A Case Report of Pulmonary Tuberculosis and Concurrent Peripheral Neuropathy. Cureus. 2025 Dec. 41523431
- [14] Claassens M, Dreyer V et al.. Whole-Genome Sequencing for Resistance Prediction and Transmission Analysis of Mycobacterium tuberculosis Complex Strains from Namibia. Microbiology spectrum. 2022 Oct 26. 36165641
- [15] Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. Journal of infection and public health. 2014 Mar-Apr. 24216518
- [16] Conradie F, Diacon AH et al.. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. The New England journal of medicine. 2020 Mar 5. 32130813
- [17] Ullah I, Shah AA et al.. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study. BMC infectious diseases. 2016 Aug 12. 27519406
- [18] Dooley KE, Hendricks B et al.. Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results. American journal of respiratory and critical care medicine. 2023 Apr 1. 36455068
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com











